Literature DB >> 29898205

Contributions by MC1R Variants to Melanoma Risk in Males and Females.

Judith Wendt1, Christoph Mueller1, Sabine Rauscher1, Ingrid Fae2, Gottfried Fischer2, Ichiro Okamoto1.   

Abstract

Importance: Recently, the red hair variants of MC1R were found to contribute differently to pigmentation phenotype in males and females. Objective: To investigate the role of these variants in melanoma risk in males and females separately because carriers of the red hair variants of MC1R are at increased risk of melanoma. Design, Setting, and Participants: In this hospital-based, case-control study, we evaluated the effect of MC1R and melanoma risk for males and females separately by performing multivariate logistic regression analyses. Main Outcomes and Measures: Association of MC1R variants and melanoma risk in males and females.
Results: A total of 905 females (473 melanoma cases, 432 controls) and 886 males (518 melanoma cases, 368 controls) were included in the analyses. The mean (SD) age of the study population was 59.2 (15.6). In females, carrying any MC1R red hair variants remained an independent risk factor of melanoma in a multivariable analysis (adjusted odds ratio [OR], 2.19 [95% CI, 1.60-2.99]), whereas in males, only signs of actinic skin damage (lentigines on the back [OR, 2.56; 95% CI, 1.47-4.45; P = .001] and the hands [OR, 2.31; 95% CI, 1.24-4.29; P = .008] and wrinkling on the neck [OR, 2.17; 95% CI, 1.23-3.82; P = .007]) and sunburns (OR, 1.65; 95% CI, 1.12-2.42; P = .01) remained significant risk factors. Conclusions and Relevance: MC1R variants contribute differently to melanoma risk in males and females. This could be helpful to better classify melanoma risk factors between the sexes.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29898205      PMCID: PMC6128491          DOI: 10.1001/jamadermatol.2018.1252

Source DB:  PubMed          Journal:  JAMA Dermatol        ISSN: 2168-6068            Impact factor:   10.282


  41 in total

1.  Melanocortin-1 receptor polymorphisms and risk of melanoma: is the association explained solely by pigmentation phenotype?

Authors:  J S Palmer; D L Duffy; N F Box; J F Aitken; L E O'Gorman; A C Green; N K Hayward; N G Martin; R A Sturm
Journal:  Am J Hum Genet       Date:  2000-01       Impact factor: 11.025

2.  Melanoma in adolescents and young adults (ages 15-39 years): United States, 1999-2006.

Authors:  Hannah K Weir; Loraine D Marrett; Vilma Cokkinides; Jill Barnholtz-Sloan; Pragna Patel; Eric Tai; Ahmedin Jemal; Jun Li; Julian Kim; Donatus U Ekwueme
Journal:  J Am Acad Dermatol       Date:  2011-11       Impact factor: 11.527

3.  Estrogen increases hair pigmentation in female recessive yellow mice.

Authors:  Tomohisa Hirobe; Megumi Kiuchi; Kazumasa Wakamatsu; Shosuke Ito
Journal:  Zoolog Sci       Date:  2010-06       Impact factor: 0.931

Review 4.  The biological actions of estrogens on skin.

Authors:  M J Thornton
Journal:  Exp Dermatol       Date:  2002-12       Impact factor: 3.960

5.  Risk factors for melanoma by body site.

Authors:  Eunyoung Cho; Bernard A Rosner; Graham A Colditz
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2005-05       Impact factor: 4.254

6.  Genetic determinants of hair, eye and skin pigmentation in Europeans.

Authors:  Patrick Sulem; Daniel F Gudbjartsson; Simon N Stacey; Agnar Helgason; Thorunn Rafnar; Kristinn P Magnusson; Andrei Manolescu; Ari Karason; Arnar Palsson; Gudmar Thorleifsson; Margret Jakobsdottir; Stacy Steinberg; Snaebjörn Pálsson; Fridbert Jonasson; Bardur Sigurgeirsson; Kristin Thorisdottir; Rafn Ragnarsson; Kristrun R Benediktsdottir; Katja K Aben; Lambertus A Kiemeney; Jon H Olafsson; Jeffrey Gulcher; Augie Kong; Unnur Thorsteinsdottir; Kari Stefansson
Journal:  Nat Genet       Date:  2007-10-21       Impact factor: 38.330

Review 7.  The role of melanocortin-1 receptor polymorphism in skin cancer risk phenotypes.

Authors:  Richard A Sturm; David L Duffy; Neil F Box; Wei Chen; Darren J Smit; Darren L Brown; Jennifer L Stow; J Helen Leonard; Nicholas G Martin
Journal:  Pigment Cell Res       Date:  2003-06

8.  Sex is an independent prognostic indicator for survival and relapse/progression-free survival in metastasized stage III to IV melanoma: a pooled analysis of five European organisation for research and treatment of cancer randomized controlled trials.

Authors:  Arjen Joosse; Sandra Collette; Stefan Suciu; Tamar Nijsten; Poulam M Patel; Ulrich Keilholz; Alexander M M Eggermont; Jan Willem W Coebergh; Esther de Vries
Journal:  J Clin Oncol       Date:  2013-05-20       Impact factor: 44.544

9.  Melanocortin 1 receptor variants in an Irish population.

Authors:  R Smith; E Healy; S Siddiqui; N Flanagan; P M Steijlen; I Rosdahl; J P Jacques; S Rogers; R Turner; I J Jackson; M A Birch-Machin; J L Rees
Journal:  J Invest Dermatol       Date:  1998-07       Impact factor: 8.551

10.  An ultraviolet-radiation-independent pathway to melanoma carcinogenesis in the red hair/fair skin background.

Authors:  Devarati Mitra; Xi Luo; Ann Morgan; Jin Wang; Mai P Hoang; Jennifer Lo; Candace R Guerrero; Jochen K Lennerz; Martin C Mihm; Jennifer A Wargo; Kathleen C Robinson; Suprabha P Devi; Jillian C Vanover; John A D'Orazio; Martin McMahon; Marcus W Bosenberg; Kevin M Haigis; Daniel A Haber; Yinsheng Wang; David E Fisher
Journal:  Nature       Date:  2012-10-31       Impact factor: 49.962

View more
  9 in total

1.  Risk Factors of Subsequent Primary Melanomas in Austria.

Authors:  Christoph Müller; Judith Wendt; Sabine Rauscher; Raute Sunder-Plassmann; Erika Richtig; Ingrid Fae; Gottfried Fischer; Ichiro Okamoto
Journal:  JAMA Dermatol       Date:  2019-02-01       Impact factor: 10.282

2.  Sex Differences in Melanoma.

Authors:  Matthew Robert Schwartz; Li Luo; Marianne Berwick
Journal:  Curr Epidemiol Rep       Date:  2019-05-31

Review 3.  Skin pigmentation and its control: From ultraviolet radiation to stem cells.

Authors:  Joseph Michael Yardman-Frank; David E Fisher
Journal:  Exp Dermatol       Date:  2020-12-24       Impact factor: 3.960

Review 4.  Melanoma Risk and Melanocyte Biology.

Authors:  Julie U Bertrand; Eirikur Steingrimsson; Fanélie Jouenne; Brigitte Bressac-de Paillerets; Lionel Larue
Journal:  Acta Derm Venereol       Date:  2020-06-03       Impact factor: 3.875

5.  Race-, Age-, and Anatomic Site-Specific Gender Differences in Cutaneous Melanoma Suggest Differential Mechanisms of Early- and Late-Onset Melanoma.

Authors:  Tze-An Yuan; Yunxia Lu; Karen Edwards; James Jakowatz; Frank L Meyskens; Feng Liu-Smith
Journal:  Int J Environ Res Public Health       Date:  2019-03-13       Impact factor: 3.390

6.  Inherited MC1R variants in patients with melanoma are associated with better survival in women.

Authors:  F E Lira; S Podlipnik; M Potrony; G Tell-Martí; N Calbet-Llopart; A Barreiro; C Carrera; J Malvehy; S Puig
Journal:  Br J Dermatol       Date:  2019-05-13       Impact factor: 9.302

7.  Cell-type-specific eQTL of primary melanocytes facilitates identification of melanoma susceptibility genes.

Authors:  Tongwu Zhang; Jiyeon Choi; William J Pavan; Kevin M Brown; Michael A Kovacs; Jianxin Shi; Mai Xu; Alisa M Goldstein; Adam J Trower; D Timothy Bishop; Mark M Iles; David L Duffy; Stuart MacGregor; Laufey T Amundadottir; Matthew H Law; Stacie K Loftus
Journal:  Genome Res       Date:  2018-10-17       Impact factor: 9.043

8.  The PI3K/mTOR Pathway Is Targeted by Rare Germline Variants in Patients with Both Melanoma and Renal Cell Carcinoma.

Authors:  Jean-Noël Hubert; Voreak Suybeng; Maxime Vallée; Tiffany M Delhomme; Eve Maubec; Anne Boland; Delphine Bacq; Jean-François Deleuze; Fanélie Jouenne; Paul Brennan; James D McKay; Marie-Françoise Avril; Brigitte Bressac-de Paillerets; Estelle Chanudet
Journal:  Cancers (Basel)       Date:  2021-05-07       Impact factor: 6.639

9.  MC1R Is a Prognostic Marker and Its Expression Is Correlated with MSI in Colorectal Cancer.

Authors:  Lixiong Peng; Jiang Chang; Xilin Liu; Shiying Lu; Honglin Ren; Xiaoshi Zhou; Zengshan Liu; Pan Hu
Journal:  Curr Issues Mol Biol       Date:  2021-10-11       Impact factor: 2.976

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.